Journal of Neuroimmune Pharmacology

, Volume 14, Issue 4, pp 531–533 | Cite as

Simvastatin Therapy in Multiple Sclerosis Patients with Respect to Gut Microbiome-Friend or Foe?

  • Mehdi ToghiEmail author
  • Sara Bitarafan
Letter to the Editor

To the Editor;

There are some reports indicating positive effect of simvastatin in promoting remyelination in multiple sclerosis (MS) patients (Kremer et al. 2018). In addition to this effect, simvastatin also reported to have beneficial effects in the treatment of secondary progressive multiple sclerosis (SPMS) (Chan et al. 2017). Despite these positive effects of simvastatin in MS pathogenesis, its effect on gut microbiome of patients has been ignored in the literature.

Prescribed pharmaceuticals along with other factors such as the host genetics, diet, lifestyle, mode of delivery and antibiotic exposure could affect gut microbiome. When these factors render the gut microbiome out of balance, there may be an induced imbalance between pro- and anti-inflammatory responses that could lead to disease. This proposed disease model is known as gut microbiome dysbiosis that results in, or are a result of, disease states. Further, gut dysbiosis has been associated with intestinal barrier...


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.


  1. Caparrós-Martín JA, Lareu RR, Ramsay JP, Peplies J, Reen FJ, Headlam HA et al (2017) Statin therapy causes gut dysbiosis in mice through a PXR-dependent mechanism. Microbiome 5(1):95CrossRefGoogle Scholar
  2. Chan D, Binks S, Nicholas JM, Frost C, Cardoso MJ, Ourselin S et al (2017) Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. Lancet Neurol 16(8):591–600CrossRefGoogle Scholar
  3. Francis A, Constantinescu CS (2018) Gastrointestinal influences in multiple sclerosis: focus on the role of the microbiome. Clin Exp Neurol 9:2–12CrossRefGoogle Scholar
  4. Kirby T, Ochoa-Repáraz J (2018) The gut microbiome in multiple sclerosis: a potential therapeutic avenue. Med Sci 6(3):69Google Scholar
  5. Ko HH, Lareu RR, Dix BR, Hughes JD (2017) Statins: antimicrobial resistance breakers or makers? PeerJ. 5:e3952CrossRefGoogle Scholar
  6. Kremer D, Akkermann R, Küry P, Dutta R (2018) Current advancements in promoting remyelination in multiple sclerosis. Mult Scler J. CrossRefGoogle Scholar
  7. Mowry EM, Glenn JD (2018) The dynamics of the gut microbiome in multiple sclerosis in relation to disease. Neurol Clin 36(1):185–196CrossRefGoogle Scholar
  8. Ohira H, Tsutsui W, Fujioka Y (2017) Are short chain fatty acids in gut microbiota defensive players for inflammation and atherosclerosis? J Atheroscler Thromb 24(7):660–672CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Medical GeneticsShahid Beheshti University of Medical SciencesTehranIran

Personalised recommendations